PwPepwise

Humanin

Energy & Cells

Mitochondrial-derived peptide (24-mer)

Humanin is a small protective peptide naturally produced by mitochondria — the energy-generating compartments found in nearly every human cell.

§Dosing at a glance

2 protocols · from the research
What it's forDoseHow oftenHowFor how long
Cell culture (in vitro)0.5–10 μg/mL———
Human indirect induction8 mg/day———

Approximate values pulled from the research — double-check before dosing.

§01Summary

Humanin is a small protective peptide naturally produced by mitochondria — the energy-generating compartments found in nearly every human cell. Discovered in the early 2000s, it is encoded within mitochondrial DNA and circulates in the bloodstream, where its levels tend to decline with age and in conditions such as type 2 diabetes and Alzheimer's disease3,19,20. In the body, humanin appears to act as a stress-response signal, helping cells survive damaging conditions by blocking programmed cell death, reducing harmful oxidative molecules, and supporting healthy energy metabolism6,12.

In human observational research, higher circulating humanin levels have been associated with preserved coronary endothelial function15 and better cognitive aging4, while children of exceptionally long-lived individuals show elevated humanin compared to peers19. Exercise may upregulate humanin within neurons, particularly in people carrying the APOE ε4 genetic variant associated with Alzheimer's risk1. In people with type 2 diabetes, combined aerobic and resistance training has been reported to significantly increase humanin levels alongside improvements in blood sugar control and inflammatory markers2. While the translational evidence base is still actively developing, humanin's broad cytoprotective actions across the brain, heart, pancreas, and metabolic tissues position it as a compelling subject of ongoing research into aging and age-related disease.

This is the layperson summary. Mechanism, dosing, the evidence base, and the published literature are in the sections below — every claim links to its source.

§02In depth

Humanin (HN) is a 24-amino-acid peptide encoded by a short open reading frame within the 16S ribosomal RNA region of human mitochondrial DNA (mtDNA). Notably, an identical open reading frame exists in the nuclear genome, suggesting ancient horizontal gene transfer from mitochondria to nucleus and potentially allowing both organelles to serve as sources of the peptide6. Humanin belongs to a broader family of mitochondrial-derived peptides (MDPs) that includes MOTS-c and the small humanin-like peptides (SHLPs 1–6), all encoded within mtDNA and collectively functioning as retrograde mitochondrial stress-response signals5,8,16.

At the molecular level, humanin exerts anti-apoptotic effects through at least two distinct mechanisms. First, it directly binds Bax protein, preventing its conformational activation and translocation from the cytosol to the outer mitochondrial membrane, thereby blocking cytochrome c release and downstream caspase activation6. Second, humanin binds insulin-like growth factor binding protein 3 (IGFBP-3) at its 18-amino-acid heparin-binding domain; this interaction suppresses IGFBP-3-induced apoptosis in a cell-type-dependent manner and synergistically enhances neuroprotection against amyloid-beta toxicity in primary cortical neurons7. Endogenous humanin protein stability is regulated post-translationally by TRIM11, a RING-finger E3 ubiquitin ligase that targets humanin for proteasomal degradation, providing a regulatory axis for modulating intracellular humanin bioavailability17.

A central receptor-mediated mechanism involves the G protein-coupled formylpeptide receptor-like 1 (FPRL1, also known as FPR2) and its murine homologue FPR2. Both humanin and amyloid-beta(42) bind and activate FPRL1, yet produce opposing cellular outcomes — humanin blocks Abeta(42)-induced aggregation, fibrillary formation, phagocyte activation, and neuronal apoptosis, suggesting biased agonism or competitive receptor occupancy as a neuroprotective strategy11. Downstream of receptor engagement and in parallel pathways, humanin activates the JAK2/STAT3 signaling axis in multiple cell types including hippocampal neurons, retinal pigment epithelial cells, pancreatic beta-cells, and hepatocytes10,12,13. In the hypothalamus, STAT3 activation mediates humanin's insulin-sensitizing effects on peripheral glucose homeostasis, with peripheral intravenous administration of humanin analogues found to exert hepatic effects via central hypothalamic relay rather than direct hepatic action9. STAT3 phosphorylation also mediates humanin's cytoprotective effects against oxidative stress in retinal cells, where humanin co-localizes with mitochondria after cellular uptake, upregulates mitochondrial transcription factor A (TFAM), and increases mitochondrial DNA copy number12.

Circulating humanin levels decline with age in humans and rodents across multiple tissues including hypothalamus, skeletal muscle, and cortex9, and are significantly reduced in metabolic disease states including type 2 diabetes20. A mitochondrial SNP (rs2854128) in the humanin-coding region reduces circulating humanin levels and is associated with accelerated cognitive aging in humans4, establishing a genotype-to-endophenotype link. Endogenous humanin expression appears upregulated as a compensatory response to mitochondrial stress — including cellular senescence, exercise, and tissue differentiation — reflecting its role as a dynamic mitochondrial status signal to distal tissues14,16.

§04Evidence & efficacy

Evidence base
234Studies
109Human
24Animal

Humanin's efficacy evidence spans multiple biological domains, with the strongest mechanistic grounding in neuroprotection, metabolic regulation, and cytoprotection, though the human interventional evidence base is still actively emerging.

Neuroprotection and Alzheimer's disease: Humanin was identified through its ability to protect neurons from Alzheimer's disease-relevant toxic insults, and its neuroprotective actions appear to involve competitive inhibition of the FPRL1/FPR2 receptor shared with amyloid-beta11 and activation of the JAK2/STAT3 signaling axis10. A potent humanin derivative, Colivelin, completely restored cognitive function in Tg2576 AD model mice10. In a human RCT, 16 weeks of exercise upregulated humanin levels in neuron-derived extracellular vesicles in AD patients, with the effect particularly pronounced in APOE ε4 carriers, suggesting that exercise-induced humanin elevation may contribute to neuroprotection in a genetically defined subgroup1. Human genetic epidemiology links a mitochondrial SNP associated with lower humanin levels to accelerated cognitive aging in a nationally representative cohort4.

Metabolic health and type 2 diabetes: Circulating humanin levels are significantly lower in people with type 2 diabetes and negatively correlate with HbA1c, fasting glucose, and triglycerides20. In a small RCT in women with T2DM, combined aerobic and resistance training significantly elevated humanin levels alongside improvements in glycemic indices, oxidative stress markers, and inflammatory cytokines, with the greatest effects seen when exercise was combined with astaxanthin supplementation2. In animal models, humanin and its analogues improve insulin sensitivity via central hypothalamic STAT3 signaling9 and protect pancreatic beta-cells from cytokine-induced apoptosis, delaying diabetes onset in NOD mice13.

Cardiovascular protection: Lower circulating humanin levels are associated with coronary endothelial dysfunction in humans15, and a humanin analogue prevented atherosclerotic plaque progression and preserved endothelial nitric oxide synthase expression in hypercholesterolemic mice independent of cholesterol levels18.

Aging and longevity: Humanin levels decline with age across multiple species but remain elevated in centenarians and their offspring3,19. Humanin overexpression extends lifespan in C. elegans via a FOXO-dependent mechanism, and HNG treatment improved metabolic healthspan in middle-aged mice19.

Cellular senescence and oxidative stress: In retinal pigment epithelial cells, humanin may protect against oxidative stress-induced senescence and mitochondrial dysfunction via STAT3 phosphorylation12, with relevance to age-related macular degeneration being investigated.

§05Safety

Human safety data for exogenously administered humanin is currently limited, as direct therapeutic dosing trials in humans have not yet been published. Available evidence is drawn from in vitro experiments, animal models, and human observational or exercise-intervention studies that measured endogenous humanin as a biomarker endpoint rather than administering the peptide therapeutically.

In preclinical settings, humanin and its analogues have demonstrated a favorable tolerability profile. Daily intraperitoneal injection of HNGF6A for 16 weeks in hypercholesterolemic mice produced no adverse effects, did not alter systemic cytokine profiles, and had no direct vasoactive effects18. Humanin treatment in NOD mice over up to 20 weeks was not associated with reported adverse events13. In cell culture, humanin treatment at 0.5–10 μg/mL did not induce cytotoxicity or detrimental effects on retinal pigment epithelial cells12.

One biologically noteworthy signal from human observational research is that humanin levels are positively correlated with total cholesterol and LDL in people with type 2 diabetes20, a finding that stands in contrast to humanin's proposed cardioprotective roles and warrants further characterization. Additionally, cross-sectional data show that the highest circulating humanin levels are observed in centenarians but are inversely correlated with survival in the oldest subjects3, a pattern consistent with hormetic biology that ongoing longitudinal research will help interpret.

In exercise-intervention RCTs measuring humanin as a biomarker endpoint, no adverse events or safety concerns related to humanin elevation were reported1,2. Exogenous humanin administration to senescent human fibroblasts appeared to selectively upregulate certain senescence-associated secretory phenotype (SASP) components, suggesting context-dependent effects on inflammatory signaling that are being actively investigated14.

§06History

Humanin was discovered in 2001 by Nishimoto and colleagues through functional cDNA library screening of surviving neurons from the occipital cortex of an Alzheimer's disease patient, identifying it as a peptide capable of rescuing neurons from AD-relevant cytotoxic insults — giving rise to its evocative name. Its sequence was found to be encoded within the 16S rRNA region of human mitochondrial DNA, a genomic location not previously associated with protein-coding capacity, which established humanin as the founding member of a new class of mitochondrial-derived peptides.

Early mechanistic work in the mid-2000s established its anti-apoptotic mechanism via direct Bax interaction6, its IGFBP-3 binding activity7, and its use of the FPRL1/FPR2 receptor shared with amyloid-beta11, collectively defining a multi-modal neuroprotective pharmacology. The identification of TRIM11 as a negative regulator of humanin stability added a key regulatory dimension17.

A major expansion of the field occurred between 2009 and 2016, when humanin's role in metabolic regulation was characterized — including its central insulin-sensitizing mechanism via hypothalamic STAT39, its beta-cell protection in autoimmune diabetes models13, and its atheroprotective properties in vascular biology18. The discovery of the broader MDP family, including MOTS-c5 and the SHLPs8, positioned humanin within a mitochondrial endocrine axis concept.

From 2018 onward, human aging and longevity cohort studies3,4,19 and the first exercise intervention RCTs measuring humanin as a biomarker1,2 have shaped the current translational landscape, with active research now focused on its potential as both a therapeutic agent and a biomarker of biological aging and metabolic health.

§07References